Key Highlights
- The nine-month net loss was USD 52.8 million, and Operating Activities used USD 44.0 million of cash, compared with USD 40.0 million of cash used in the same period of 2025.
- Cash, cash equivalents and short-term investments totalled USD 19.5 million at September 30, 2026, which management says will be insufficient to meet its needs without additional capital.
- Research and development expense climbed to USD 44.1 million for nine months from USD 26.5 million, driven by two Phase 2 studies of rademikibart in asthma and COPD.
- The company plans to meet the FDA in December 2026 on a possible Phase 3 asthma program and in the first quarter of 2027 for COPD.
Cash Runway Falls Short of the Plan
Connect Biopharma (NASDAQ:CNTB) filed its Quarterly Report on November 16, 2026, and it carries a blunt message on funding. The San Diego-based clinical-stage company develops rademikibart, an anti-interleukin-4-receptor Alpha antibody, and holds USD 19.5 million of cash, equivalents and short-term investments. Management says that amount will be insufficient to meet its cash needs and states that substantial doubt exists about its ability to continue as a going concern. The nine-month net loss reached USD 52.8 million, with USD 44.0 million of cash used in operations. Historically it has funded itself through securities sales, including its March 2021 initial public offering that raised USD 219.9 million before fees, and through payments under collaboration agreements. It also leases laboratory and office space in Taicang, China.
Phase 2 Data in Asthma and COPD
In September 2026 the company reported topline Phase 2 results. In asthma, rademikibart lifted post-bronchodilator FEV1 by 250 mL against 120 mL for placebo at Day 7 (p=0.023), while a roughly 66% cut in treatment failure missed significance (p=0.153) because the overall failure rate was lower than projected. In COPD, treatment failure fell 81% through Week 4 (p=0.0122) and new exacerbations fell 85% (p=0.0301). The company says the drug was well tolerated, with no new safety signals. It adds that the smaller COPD lung-function gain of 70 mL (p=0.1607) likely reflects fixed airflow limitation in that population.
Spending, Financing and the Cantor Facility
Research and development expense reached USD 44.1 million for nine months versus USD 26.5 million, while general and administrative expense fell to USD 13.1 million from USD 16.1 million on lower professional fees. License and collaboration Revenue was USD 3.7 million, mostly a regulatory milestone under the Simcere agreement. Financing brought in USD 18.9 million, led by a private Placement of 6,130,000 shares with net proceeds of USD 18.6 million. In October 2026 the company sold 1.5 million shares through a Cantor Facility of up to USD 150.0 million for net proceeds of USD 1.8 million. Other income, net, shrank to USD 0.8 million from USD 2.3 million on lower interest income and subsidies.
Where Things Stand
On the filing alone, funding is the open question, not the data. Connect Biopharma has USD 19.5 million against nine-month cash burn of USD 44.0 million, and management says it will need additional Capital before any Phase 3 program can start. The December 2026 FDA meeting on asthma and the first-quarter 2027 meeting on COPD are the next markers, along with further use of the Cantor facility, which adds shares and dilution for existing holders if it is drawn.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...